Schizophrenia and Genomics by Lasch, Tiffini
Otterbein University 
Digital Commons @ Otterbein 
Nursing Student Class Projects (Formerly MSN) Student Research & Creative Work 
Summer 2020 
Schizophrenia and Genomics 
Tiffini Lasch 
Otterbein University, lasch1@otterbein.edu 
Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn 
 Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Mental 
Disorders Commons, Nursing Commons, and the Psychiatric and Mental Health Commons 
Recommended Citation 
Lasch, Tiffini, "Schizophrenia and Genomics" (2020). Nursing Student Class Projects (Formerly MSN). 
440. 
https://digitalcommons.otterbein.edu/stu_msn/440 
This Project is brought to you for free and open access by the Student Research & Creative Work at Digital 
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an 




Tiffini Lasch, BSN, RN 
Introduction Signs and Symptoms Additional 
Sources
American Foundation for Suicide 
Prevention . (n.d.). 
https://afsp.org/
Genetic Home Reference. (n.d.). 
https://ghr.nlm.nih.gov/primer/ge
nomicresearch/gwastudies
Mental Health Information. (n.d.). 
https://www.nimh.nih.gov/health/
index.shtml











• Cognitive issue effecting thought 
process
• Emotionless (Schizophrenia, n.d.)
• Lack of motivation
• Lack of planning
• Disorganized thoughts
• Lack of pleasure
• Abnormal movements
• Impaired memory and
concentration (Patient & Families: 
Schizophrenia, n.d.)
Complications
• Financial problems and homeless
• Other mental health co-morbidities
• Substance abuse
• Suicide Ideation (Mayo Clinic, n.d.)
(Figure 1)
The findings displayed from Knochel et 
al., 2017 study showing the protein 
levels correlation between controls, SZ, 








• Genomics has been added to the 
Scope and Standards of Practice by 
the ANA.
• The Advanced Practice Nurse 
should be prepared for continual up 
to date education for genomic and
SZ.
• Clinicians need to have a full
understanding of
pharmacogenomics. 
• Be prepared to educate patients 
understandably based on their
culture, knowledgebase, reading
capability, and language.
• Present all aspects of genomics with
patients.  There are both ethical and
legal issues to consider.
• Be able to perform a risk
assessment to relay information to
pharmacists, genetic counselors,
and geneticists (McCormick, 2017)
• Patients with Schizophrenia (SZ) 
struggle to determine reality vs.
non-reality.  This 
neurodevelopmental disorder is 
not short-lived.  Instead, SZ 
requires life-time treatment.
Factors that impact SZ include
genetics, environment, and brain 
disruptions (Mental Health
Information, n.d.). SZ is usually
discovered between the ages of 16 
and 30. Most people do not
develop SZ after the age of 45.
Currently, a cure is not available 
(Schizophrenia, n.d.).
• Genomics is one of the future paths 
to better medicine.  The purpose of 
this article is to understand how 
genetic studies can lead to 
improved treatment of SZ.
• This topic was chosen to bring
awareness to what genomics can
do for those who have SZ and
acknowledge the need for more 
studies to be completed. There 
have been astonishing
advancement in gene therapy.
Gene therapy provides a cure for 
certain cancers (Roth, 2019).
However, there has been a lack of 
studies for analyzing rare non-
coding variants for SZ (Takata,
2019). The mental health charity 
showed that the United Kingdom
spent 5.5 % of its budget on 
mental illness and 19.6% on 
cancer, even though mental health
is a more significant burden (Kong
et al., 2017).
• The genome-wide association 
studies have found a genic
correlation between mental
disorders, polygenic heritability, 
and other brain disorders. There 
are over 150 genome-wide hits for 
SZ, but there is a lack of
transitioning this knowledge to
public mental health.  The lack of 
transition into public mental
health is due to a lack of education
for clinicians. This ongoing
insufficient movement is why it is 
important to start discussing and
educating. There is an urgent need 
to keep working on discoveries.
(Merikngas & Merikangas, 2019).
• Not all scientists support genetics as 
the alone cause of SZ. However, having 
an individual genetic predisposition 
may be influenced by other factors.
• Mothers who have been exposed to
viruses have an increased chance their 
child will have SZ.
• Viruses can also attack the brain cells,
lay dormant, affect neurotransmitters, 
and alter brain cell processes.
• Exposure to lead, such as lead found in
lead paint.
• Evidence supporting people who have 
the herpes simplex virus and
cytomegalovirus have antibodies that
can cause genes to develop SZ.
• Antibodies to toxoplasmosis gondii 
have been associated with SZ.
• Someone is more likely to develop SZ 
in metropolitan areas versus rural
areas..
• Women in famine during pregnancy 
have an increased chance of having a 
child with SZ (Cause and Risk Factors 
of Schizophrenia, n.d.)
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Nursing Implications 
• Research is changing rapidly, and 
clinicians need to stay on top of new 
data to manage their patients' care 
properly. There have been many 
advancements in genomics related to 
SZ, such as phenotypes are 
polygenic, DNA methylation of COMT 
can lead to biomarkers, and the 
correlation with cognitive 
impairment and SZ. There is an 
ongoing issue with funding for 
genomic studies toward mental 
health disorders. Mental health 
studies are funded less compared to 
that of cancer. All three studies 
discussed in this project ends with a 
cautionary note that the study of 
genomic and SZ still require further 
investigation.  As long as more 
extensive research is completed, 
there is hope for more quality 
outcomes.
,
• Large genome-wide associated
studies (GWAS), have made 
advancements in understanding
genic make-up and SZ.  SZ is not 
determined by just one gene. There 
is estimated to be over 100 risk
gene loci. Correlation between
cognitive and gene factors SZ has 
also been noted.  It is believed the 
phenotypes are polygenic. The 
strongest correlation lies in 
chromosome 22q13.2.
• There is a 60 to 80% chance SZ will
be passed on to children, and family 
members who do not express the 
traits still have
Pathophysiology Genetic Factors
• A study conducted by Knochel et al., 
2017, researched genomics to
discover protein levels that reflect SZ 
and bipolar disorder's 
pathophysiology.  They  also used a 
trans-diagnostic approach with MRI
measurements and found differing 
protein levels; see figure 1.  ApoC also 
differed between participants and 
showed correlations to cogitative 
impairment.  Furthermore, ApoC 
showed a relationship between 
hippocampus volumes and the 
severity of impairment. The more 
cognitive issues a participant had, the 
more considerable changes in Apo 
concentrations.   Findings showed that 
low hippocampal (HC)
• a chance their children will have 
cognitive and psychiatric issues.
• Those diagnosed with SZ have shown 
notable amounts of cognitive
impairment with insight, judgment,
memory, and concentration. Another
correlation is that premorbid
cognitive issues are related to later
developing psychotic disorders 
(Smeland & Andreassen, 2018).
• volume equaled increased ApoC.
• A study conducted with catechol-O-
methyltransferase (COMT) DNA
methylation extracted from the 
peripheral blood using a linear
regression analysis showed the 
relationship between COMT DNA 
methylation and excitement and
depression symptoms of SZ (Nou El
Huda et al., 2018).
Image retrieved from: https://www.123rf.com/photo_52545507_photo-of-psychotic-
woman-with-schizophrenia-during-treatment.html?vti=mqkdlco09ouubr98fm-1-8
• Currently, no treatment exists for
cognitive dysfunction for those 
with SZ. Cognitive function can be
a predictor of overall life outcomes 
in psychotic disorder.
• Researchers are gaining more 
biological insight to discover
treatments. The Psychiatric
Genomics Consortium is gaining
recognition for advancement in 
analyzing genetic data.  However, 
new statistical procedures are 
required to discover the missing
genetic links.
• By discovering a single gene 
characteristic, it has become 
possible to make advancements in
target drugs. The FDR method has 
been utilized to reference SZ with
other traits, and when another
trait is recognized to co-exist with
a SZ trait, that information can be 
used to prioritize by suggestive 
association (Smeland &
Andreassen, 2018).
• Apo can be used as biomarkers for
psychomotor speed, executive 
functioning, and intelligence,
which can be SZ indicators.
• Low volumes in HC can mean more 
suffering for those with SZ. More 
care measures can be 
implemented.
• Findings from Knochel et al., 2017, 
and GWAS may lead to finding
biological diagnostic tools for SZ 
(Knochel et al., 2017).
• DNA methylation of COMT in 
peripheral blood can be used for
biomarkers for SZ. The event of
hyperfunction of dopamine 
suggest the methylation-gene 
expression is difficult to obtain 
correctness due to methods used
and demographics, and the 
dopamine hypothesis of SZ may 
not hold (Nour El Huda et al.,
2018).
Conclusion
